GT Biopharma (GTBP) Invested Capital (2010 - 2021)

GT Biopharma (GTBP) has reported Invested Capital for 12 consecutive years, with $31000.0 the latest figure, recorded in Q4 2021.

• In Q4 2021, Invested Capital fell 99.88% year-over-year to $31000.0; the TTM figure through Sep 2022 stood at $31000.0 (down 99.88% YoY), while the FY2021 annual figure was $31000.0, down 99.88% from the prior year.
• Invested Capital fell to $31000.0 in Q4 2021 per GTBP's latest filing, from $26.3 million in the prior quarter.
• Across five years, Invested Capital topped out at $26.3 million in Q4 2020 and bottomed at $31000.0 in Q4 2021.
• Historically, Invested Capital has averaged $11.1 million across 5 years, with a median of $11.3 million in 2019.
• Annual changes were most pronounced in 2018 — Invested Capital surged 712.32% — and 2021, when it sank 99.88%.
• GT Biopharma's Invested Capital stood at $844000.0 in 2017, then soared by 1164.57% to $10.7 million in 2018, then increased by 23.74% to $13.2 million in 2019, then jumped by 99.16% to $26.3 million in 2020, then tumbled by 99.88% to $31000.0 in 2021.
• Business Quant data shows GTBP's Invested Capital at $31000.0 in Q4 2021, $26.3 million in Q4 2020, and $23.0 million in Q3 2020.